It has been estimated to cost ~1 billion US dollars to bring a drug to the market. This partly reflects the challenge to identify targets that translate into effective and safe medication. Compounds that show promising results in vitro don’t always exert effects in humans. Animal studies are typically expensive, time-consuming and ethically challenging.

Our pioneering approach uses systematic gene editing, in vivo imaging and deep learning based image analysis to comprehensively scrutinize the role of hundreds of potential targets using live zebrafish larvae. Our results to date show that genes affecting traits related to common cardiometabolic diseases in zebrafish larvae are enriched for common and rare variant associations with those diseases in humans. Our unique ability, experience and track record are compelling reasons to collaborate with us, so you can develop drugs quicker and cheaper.

We represent a state-of-the-art lab focusing on standardization, automation, objective quantification, robust results, and risk assessment. Based on the results of an outsourced market analysis, and to the best of our knowledge, Veyviser is the first solution of its kind for complex cardiometabolic diseases. From zebrafish husbandry in a state-of-the-art new facility, to micro-injections at the single cell stage for CRISPR/Cas9-based gene perturbation, raising and challenging of larvae under standardized conditions, automated in vivo fluorescence and bright field imaging, deep learning-based neural networks for image analysis trained using 1000s of images, and ascertainment of mutagenesis: all steps of the pipeline have been meticulously thought through and optimized. We continue to work at the forefront of methods development to further optimize our workflow and offering.